Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Avery A Rizio, Michelle K White, Anita D’Souza, Kristen Hsu, Paula Schmitt, Tiffany P Quock, James Signorovitch, Isabelle Lousada & Vaishali Sanchorawala. (2023) Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group. Patient Related Outcome Measures 14, pages 153-169.
Read now
Read now
Efstathios Kastritis, Arpit Misra, Laura Gurskyte, Florint Kroi, Andre Verhoek, Jessica Vermeulen, Eric Ammann, Annette Lam, Sarah Cote & Ashutosh D. Wechalekar. (2023) Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis. Hematology 28:1.
Read now
Read now
Avery A Rizio, Kristen L McCausland, Michelle K White & Tiffany P Quock. (2021) Work Outcomes Among Patients with Light Chain (AL) Amyloidosis: Findings from Three Patient Cohorts. Patient Related Outcome Measures 12, pages 339-347.
Read now
Read now
Anita D’Souza, Brooke E. Magnus, Judith Myers, Angela Dispenzieri & Kathryn E. Flynn. (2020) The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid 27:2, pages 111-118.
Read now
Read now
Rajshekhar Chakraborty, Lisa Rybicki, Jacqulyn Tomer, Christy J. Samaras, Beth M. Faiman, Jason Valent & Navneet S. Majhail. (2019) Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population. Leukemia & Lymphoma 60:14, pages 3544-3551.
Read now
Read now
Michelle K White, Kristen L McCausland, Vaishali Sanchorawala, Spencer D Guthrie & Martha S Bayliss. (2017) Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Related Outcome Measures 8, pages 157-167.
Read now
Read now
Huamao Mark Lin, Xin Gao, Catherine E. Cooke, Deborah Berg, Richard Labotka, Douglas V. Faller, Brian Seal & Parameswaran Hari. (2017) Disease burden of systemic light-chain amyloidosis: a systematic literature review. Current Medical Research and Opinion 33:6, pages 1017-1031.
Read now
Read now
John-Paul Carter, Darren Foard, Lisa Rannigan, Kamela Aliaz, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Cristina Quarta, Ana Martinez De Azcona Naharro, Taryn Youngstein, Tamer Rezk, Ashutosh Wechalekar, Carol Whelan, Helen Lachmann, Philip Hawkins, Julian Gillmore & Thirusha Lane. (2017) A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid 24:sup1, pages 72-73.
Read now
Read now
Articles from other publishers (20)
Anita D'Souza, Aniko Szabo, Idayat Akinola, Muriel Finkel & Kathryn E. Flynn. (2023)
Differences in patient‐reported outcomes (
PROs
) by disease severity in light chain (
AL
) amyloidosis
. European Journal of Haematology 111:4, pages 536-543.
Crossref
Crossref
Michelle L. Mauermann, John O. Clarke, William J. Litchy, Laura Obici, Isabelle Lousada, Morie A. Gertz, Yolanda Barbachano, Melanie Blank, Michelle Campbell, Douglas Faller, Kristen Hsu, Laura Jawidzik, Kathy Koontz, Matthew Kowalik, Sarrit Kovacs & James Signorovitch. (2023) Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group. Advances in Therapy.
Crossref
Crossref
Anita D’Souza, Aniko Szabo, Idayat Akinola, Muriel Finkel & Kathryn E. Flynn. (2023) A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis. Quality of Life Research 32:6, pages 1807-1817.
Crossref
Crossref
Georges Khalil, Dimitri Fiani, Fares Antaki & Ernest Diab. (2023) Primary gastric amyloidosis associated with linitis plastica and delayed progression to systemic amyloidosis and multiple myeloma. BMJ Case Reports 16:5, pages e252786.
Crossref
Crossref
Oliver Cohen, Regina Rendas‐Baum, Kristen McCausland, Darren Foard, Richa Manwani, Sriram Ravichandran, Helen Lachmann, Shameem Mahmood, Brendan Wisniowski, Philip N. Hawkins, Julian Gillmore, Kristen Hsu, Sabrina Rebello & Ashutosh Wechalekar. (2023) Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis. British Journal of Haematology 201:3, pages 422-431.
Crossref
Crossref
Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan O. Schönland, Heather J. Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Dasha Cherepanov, Vanessa C. Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller & Efstathios Kastritis. (2023)
Quality of life and symptoms among patients with relapsed/refractory
AL
amyloidosis treated with
ixazomib‐dexamethasone
versus physician's choice
. American Journal of Hematology 98:5, pages 720-729.
Crossref
Crossref
Andreas Thimm, Alexander Carpinteiro, Sara Oubari, Maria Papathanasiou, Peter Luedike, Lukas Kessler, Christoph Rischpler, Tobias Blau, Hans Christian Reinhardt, Tienush Rassaf, Hartmut Schmidt, Christoph Kleinschnitz & Tim Hagenacker. (2022) Prevalence and predictors of neurological manifestations in systemic AL amyloidosis. Journal of the Neurological Sciences 440, pages 120341.
Crossref
Crossref
Bou Zerdan Maroun, Sabine Allam & Chakra P. Chaulagain. (2022) Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Research 57:2, pages 106-116.
Crossref
Crossref
Mathew S. Maurer, Preston DunnmonMariana FontanaCristina Candida QuartaKrishna PrasadRonald M. Witteles, Claudio RapezziJames Signorovitch, Isabelle Lousada & Giampaolo Merlini. (2022) Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure 15:6.
Crossref
Crossref
Vaishali Sanchorawala, Giovanni Palladini, Monique C. Minnema, Arnaud Jaccard, Hans C. Lee, Simon Gibbs, Peter Mollee, Christopher Venner, Jin Lu, Stefan Schönland, Moshe Gatt, Kenshi Suzuki, Kihyun Kim, María Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Sandy W. Wong, Michael Rosenzweig, Naresh Bumma, Dominique Chauveau, Katharine S. Gries, John Fastenau, Nam Phuong Tran, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Kai Fai Ho, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis & Ashutosh D. Wechalekar. (2022)
Health‐related quality of life in patients with
light chain
amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the
ANDROMEDA
study
. American Journal of Hematology 97:6, pages 719-730.
Crossref
Crossref
Andreas Thimm, Alexander Carpinteiro, Sara Oubari, Maria Papathanasiou, Lukas Kessler, Christoph Rischpler, Rayaz Ahmed Malik, Hans Christian Reinhardt, Tienush Rassaf, Ken Herrmann, Christoph Kleinschnitz, Mark Stettner & Tim Hagenacker. (2022)
Corneal confocal microscopy to detect early immune‐mediated small nerve fibre loss in
AL
amyloidosis
. Annals of Clinical and Translational Neurology 9:6, pages 853-863.
Crossref
Crossref
Anita D’Souza, Judith Myers, Rachel Cusatis, Angela Dispenzieri, Muriel Finkel, Julie Panepinto & Kathryn E. Flynn. (2021) Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. Quality of Life Research 31:4, pages 1083-1092.
Crossref
Crossref
Hamza Hassan & Vaishali Sanchorawala. (2022) Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs. Hemato 3:1, pages 38-46.
Crossref
Crossref
Melanie Blank, Michelle Campbell, John O. Clarke, Raymond Comenzo, Laura M. Dember, Angela Dispenzieri, Sharmila Dorbala, Preston Dunnmon, Douglas V. Faller, Rodney H. Falk, Nicole Gormley, Kristen Hsu, Carol D. Karp, Heather Landau, Jessica L. Lee, Isabelle Lousada, Michelle L. Mauermann, Mathew Maurer, Vaishali Sanchorawala, James Signorovitch, Kimberly Smith, Ashutosh D. Wechalekar, Brendan M. Weiss, Michelle K. White & Isabelle Lousada. (2020) The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Sandy W. Wong & Teresa Fogaren. (2020) Supportive Care for Patients with Systemic Light Chain Amyloidosis. Hematology/Oncology Clinics of North America 34:6, pages 1177-1191.
Crossref
Crossref
Michelle K. White, Martha S. Bayliss, Spencer D. Guthrie, Kimberly P. Raymond, Avery A. Rizio & Kristen L. McCausland. (2017) Content validation of the SF-36v2® health survey with AL amyloidosis patients. Journal of Patient-Reported Outcomes 1:1.
Crossref
Crossref
Martha Bayliss, Kristen L. McCausland, Spencer D. Guthrie & Michelle K. White. (2017) The burden of amyloid light chain amyloidosis on health-related quality of life. Orphanet Journal of Rare Diseases 12:1.
Crossref
Crossref
Rahma Warsame, Shaji K. Kumar, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, David Dingli, John A. Lust, Yi Lin, Stephen Russell, Prashant Kapoor, Ronald S. Go, Taxiarchis Kourelis, Wilson Gonsalves, Steven R. Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Tyler Zemla, Jeffrey Sloan & Angela Dispenzieri. (2017) Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology 92:5, pages 435-440.
Crossref
Crossref
S Y Lee, R S Meehan, D C Seldin, J M Sloan, K Quillen, A Shelton, D Brauneis & V Sanchorawala. (2016) Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation 51:10, pages 1318-1322.
Crossref
Crossref
Jessica Tsukanov & Egidio Del Fabbro. (2016) Palliative care and symptom management in amyloidosis: A review. Current Problems in Cancer 40:5-6, pages 220-228.
Crossref
Crossref